View Item 

Show simple item record

Host‐Response Therapeutics for Periodontal Diseases
dc.contributor.authorGiannobile, William V.
dc.date.accessioned2018-02-05T16:28:30Z
dc.date.available2018-02-05T16:28:30Z
dc.date.issued2008-08
dc.identifier.citationGiannobile, William V. (2008). "Host‐Response Therapeutics for Periodontal Diseases." Journal of Periodontology 79: 1592-1600.
dc.identifier.issn0022-3492
dc.identifier.issn1943-3670
dc.identifier.urihttps://hdl.handle.net/2027.42/141161
dc.publisherWiley Periodicals, Inc.
dc.publisherAmerican Academy of Periodontology
dc.subject.otherperiodontitis
dc.subject.otherBisphosphonates
dc.subject.otherbone resorption
dc.subject.othermatrix metalloproteinases
dc.titleHost‐Response Therapeutics for Periodontal Diseases
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Biomedical Engineering, College of Engineering, University of Michigan.
dc.contributor.affiliationotherDepartment of Periodontics and Oral Medicine, School of Dentistry, Michigan Center for Oral Health Research, Ann Arbor, MI.
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141161/1/jper1592.pdf
dc.identifier.doi10.1902/jop.2008.080174
dc.identifier.sourceJournal of Periodontology
dc.identifier.citedreferenceTenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002; 73: 813 – 822.
dc.identifier.citedreferenceCiancio S, Ashley R. Safety and efficacy of sub‐antimicrobial‐dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998; 12: 27 – 31.
dc.identifier.citedreferenceCaton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000; 71: 521 – 532.
dc.identifier.citedreferenceReddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti‐inflammatory, and bone‐sparing agents. A systematic review. Ann Periodontol 2003; 8: 12 – 37.
dc.identifier.citedreferencePreshaw PM, Novak MJ, Mellonig J, et al. Modified‐release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol 2008; 79: 440 – 452.
dc.identifier.citedreferenceGapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: A proof of concept trial. J Periodontol 2004; 75: 441 – 452.
dc.identifier.citedreferencePayne JB, Stoner JA, Nummikoski PV, et al. Subantimicrobial dose doxycycline effects on alveolar bone loss in post‐menopausal women. J Clin Periodontol 2007; 34: 776 – 787.
dc.identifier.citedreferenceReinhardt RA, Stoner JA, Golub LM, et al. Efficacy of sub‐antimicrobial dose doxycycline in post‐menopausal women: Clinical outcomes. J Clin Periodontol 2007; 34: 768 – 775.
dc.identifier.citedreferenceGolub LM, Lee HM, Stoner JA, et al. Subantimicrobial‐dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol 2008; 79: 1409 – 1418.
dc.identifier.citedreferenceNuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: New challenges in the era of post broad‐spectrum inhibitors. Curr Pharm Des 2007; 13: 2087 – 2100.
dc.identifier.citedreferenceKamel HK. Update on osteoporosis management in long‐term care: Focus on bisphosphonates. J Am Med Dir Assoc 2007; 8: 434 – 440.
dc.identifier.citedreferenceJeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, Norton LA, eds. Biological Mechanisms of Tooth Movement and Craniofacial Adaptation,vol. 1. Cambridge, MA: Harvard Society for the Advancement of Orthodontics; 1996: 365 – 373.
dc.identifier.citedreferenceRocha M, Nava LE, Vázquez de la Torre C, Sánchez‐Marin F, Garay‐Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo‐controlled trial. J Periodontol 2001; 72: 204 – 209.
dc.identifier.citedreferenceTakaishi Y, Miki T, Nishizawa Y, Morii H. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: Report of four cases. J Int Med Res 2001; 29: 355 – 365.
dc.identifier.citedreferenceLane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12‐month, randomized, placebo‐controlled study. J Periodontol 2005; 76: 1113 – 1122.
dc.identifier.citedreferenceWang HL, Weber D, McCauley LK. Effect of long‐term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol 2007; 78: 584 – 594.
dc.identifier.citedreferenceFicarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32: 1123 – 1128.
dc.identifier.citedreferenceKhosla S, Burr D, Cauley J, et al. Bisphosphonate‐associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479 – 1491.
dc.identifier.citedreferenceExpert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw. Available at: http://www.fda.gov/OHRMS/DOCKETS/AC/05/briefing/2005‐4095B2_02_12‐Novartis‐Zometa‐App‐11.pdf. Accessed January 23, 2008.
dc.identifier.citedreferenceAmerican Academy of Periodontology. AAP statement on bisphosphonates. http://www.perio.org/resources‐products/bisphosphonates.htm. Published 2005. Accessed May 30, 2008.
dc.identifier.citedreferenceKinney JS, Ramseier CA, Giannobile WV. Oral fluid‐based biomarkers of alveolar bone loss in periodontitis. Ann N Y Acad Sci 2007; 1098: 230 – 251.
dc.identifier.citedreferenceAlbandar JM. Periodontal diseases in North America. Periodontol 2000 2002; 29: 31 – 69.
dc.identifier.citedreferenceWoodward JK, Holen I, Coleman RE, Buttle DJ. The roles of proteolytic enzymes in the development of tumour‐induced bone disease in breast and prostate cancer. Bone 2007; 41: 912 – 927.
dc.identifier.citedreferencePussinen PJ, Paju S, Mantyla P, Sorsa T. Serum microbial‐ and host‐derived markers of periodontal diseases: A review. Curr Med Chem 2007; 14: 2402 – 2412.
dc.identifier.citedreferenceauf dem Keller U, Doucet A, Overall CM. Protease research in the era of systems biology. Biol Chem 2007; 388: 1159 – 1162.
dc.identifier.citedreferenceRa HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007; 26: 587 – 596.
dc.identifier.citedreferenceTester AM, Cox JH, Connor AR, et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP‐8 activity. PLoS ONE 2007; 2: e312.
dc.identifier.citedreferenceGill SE, Parks WC. Metalloproteinases and their inhibitors: Regulators of wound healing. Int J Biochem Cell Biol 2007; 40: 1334 – 1347.
dc.identifier.citedreferenceLópez‐Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800 – 808.
dc.identifier.citedreferenceSorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006; 38: 306 – 321.
dc.identifier.citedreferenceGolub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase inhibitor reduces bone‐type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997; 46: 310 – 319.
dc.identifier.citedreferenceHerr AE, Hatch AV, Giannobile WV, et al. Integrated microfluidic platform for oral diagnostics. Ann N Y Acad Sci 2007; 1098: 362 – 374.
dc.identifier.citedreferenceHerr AE, Hatch AV, Throckmorton DJ, et al. Microfluidic immunoassays as rapid saliva‐based clinical diagnostics. Proc Natl Acad Sci USA 2007; 104: 5268 – 5273.
dc.identifier.citedreferenceKinane DF, Darby IB, Said S, et al. Changes in gingival crevicular fluid matrix metalloproteinase‐8 levels during periodontal treatment and maintenance. J Periodontal Res 2003; 38: 400 – 404.
dc.identifier.citedreferenceKirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43: 294 – 315.
dc.identifier.citedreferenceGolub LM, Payne JB, Reinhardt RA, Nieman G. Can systemic diseases co‐induce (not just exacerbate) periodontitis? A hypothetical “two‐hit” model. J Dent Res 2006; 85: 102 – 105.
dc.identifier.citedreferenceGolub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992; 2: 80 – 90.
dc.identifier.citedreferenceWilliams RC. Periodontal disease. N Engl J Med 1990; 322: 373 – 382.
dc.identifier.citedreferenceOlsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167 – 2179.
dc.identifier.citedreferenceAshley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci 1999; 878: 335 – 346.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jper1592.pdf
Size:
1.639MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.